MCID: ADN009
MIFTS: 54

Adenosquamous Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 14 69
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 41
Carcinoma Adenosquamous 51

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 41 D018196
NCIt 46 C3727
SNOMED-CT 64 403902008 59367005
UMLS 69 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to adenosquamous pancreas carcinoma and adenosquamous cell lung carcinoma. An important gene associated with Adenosquamous Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Developmental Biology and Downstream signaling events of B Cell Receptor (BCR). The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and pancreas, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 72 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 adenosquamous pancreas carcinoma 32.2 KRAS KRT5 KRT7 PTHLH
2 adenosquamous cell lung carcinoma 31.8 EGFR KRAS PDGFRA
3 adenocarcinoma 30.6 EGFR KRAS MUC1 MUC4 TP53
4 cervical adenocarcinoma 30.5 EGFR KRT7 TP53
5 ampulla of vater neoplasm 30.3 KRAS KRT7 MUC1
6 syringocystadenoma papilliferum 30.3 KRAS MUC1
7 cystadenoma 30.0 KRT7 MUC1 MUC4
8 dermoid cyst 29.9 KRT7 MUC1 TP63
9 hidradenoma 29.9 KRT7 MUC1
10 cystadenocarcinoma 29.9 KRT7 MUC1 TP53
11 squamous cell carcinoma 29.6 EGFR KRT7 MUC1 PTHLH TP53 TP63
12 mucoepidermoid carcinoma 29.5 EGFR KRT7 MUC1 MUC4 TP63
13 cholecystitis 29.5 KRT18 MUC1 TP53
14 necrotizing sialometaplasia 29.5 KRT5 KRT7 TP53 TP63
15 pancreatic ductal adenocarcinoma 29.3 EGFR KRAS MUC1 MUC4 TP53
16 papilloma 29.1 KRT5 KRT7 KRT8 TP53 TP63
17 small cell carcinoma 29.1 EGFR KRT7 PDGFRA TP53
18 lymphoepithelioma-like carcinoma 29.0 KRT18 KRT5 KRT7 KRT8 MUC1
19 lung squamous cell carcinoma 29.0 EGFR KRAS PTHLH TP53 TP63
20 hepatocellular carcinoma 28.8 EGFR KRAS KRT18 KRT7 KRT8 TP53
21 large cell carcinoma 28.2 EGFR KRT5 KRT7 PDGFRA PTHLH TP63
22 lung cancer 27.8 EGFR KRAS KRT18 KRT7 MUC4 PTHLH
23 glassy cell variant cervical adenosquamous carcinoma 12.3
24 endometrial adenosquamous carcinoma 12.2
25 gastric adenosquamous carcinoma 12.2
26 cervical adenosquamous carcinoma 12.2
27 esophageal adenosquamous carcinoma 12.2
28 thymus adenosquamous carcinoma 12.2
29 bartholin's gland adenosquamous carcinoma 12.0
30 ampulla of vater adenosquamous carcinoma 12.0
31 adenosquamous colon carcinoma 11.5
32 adenosquamous prostate carcinoma 11.5
33 adenosquamous gallbladder carcinoma 11.5
34 adenosquamous bile duct carcinoma 11.0
35 paronychia 10.6 EGFR KRAS
36 tumor suppressor gene on chromosome 11 10.5 EGFR KRAS
37 breast scirrhous carcinoma 10.5 EGFR MUC1
38 malignant peritoneal mesothelioma 10.5 EGFR MUC1
39 apocrine adenoma 10.5 KRAS MUC1
40 oncocytic breast carcinoma 10.5 EGFR KRT7
41 anal canal adenocarcinoma 10.5 KRAS KRT7
42 inverted transitional papilloma 10.5 KRT5 KRT7
43 endosalpingiosis 10.5 KRT7 MUC1
44 glandular cystitis 10.5 KRT7 MUC1
45 balloon cell malignant melanoma 10.5 KRT5 KRT7
46 parachordoma 10.5 KRT7 MUC1
47 sensory organ benign neoplasm 10.5 KRT5 KRT7
48 endolymphatic sac tumor 10.5 KRT7 KRT8
49 malignant mixed mullerian tumor 10.5 KRT7 MUC1
50 mucinous bronchioloalveolar adenocarcinoma 10.5 KRT7 MUC1

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

25 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.16 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-154 10.16 KRT18
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.16 KRT18 KRT5 CCT2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.16 KRT5 KRT8
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.16 KRT5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.16 KRT18
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.16 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.16 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.16 KRT18 KRT5 KRT7 KRT8
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.16 KRT7
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.16 KRT18 CCT2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.16 KRT5 KRT7
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.16 CCT2
14 Decreased viability GR00055-A-2 9.32 EGFR KRAS MUC1
15 Decreased viability GR00106-A-0 9.32 KRAS
16 Decreased viability GR00221-A-1 9.32 EGFR KRAS
17 Decreased viability GR00221-A-2 9.32 KRAS
18 Decreased viability GR00221-A-4 9.32 EGFR
19 Decreased viability GR00301-A 9.32 KRAS
20 Decreased viability GR00381-A-1 9.32 KRAS

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 KRT5 TP53 EGFR KRT8 PDGFRA KRAS
2 growth/size/body region MP:0005378 10.06 KRAS PTHLH KRT18 KRT5 KRT8 EGFR
3 craniofacial MP:0005382 10.02 PTHLH KRT5 TP53 EGFR PDGFRA KRAS
4 embryo MP:0005380 9.98 KRT18 TP53 KRT8 EGFR PDGFRA KRAS
5 integument MP:0010771 9.91 KRAS PTHLH KRT5 EGFR PDGFRA TP53
6 limbs/digits/tail MP:0005371 9.87 PTHLH KRT5 TP53 EGFR PDGFRA KRAS
7 no phenotypic analysis MP:0003012 9.73 KRAS KRT5 EGFR PDGFRA TP53 TP63
8 renal/urinary system MP:0005367 9.7 PTHLH TP53 KRT7 EGFR PDGFRA KRAS
9 reproductive system MP:0005389 9.5 KRAS PTHLH KRT8 EGFR PDGFRA TP53
10 respiratory system MP:0005388 9.1 KRAS PTHLH EGFR PDGFRA TP53 TP63

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
7
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Vinblastine Approved Phase 3 865-21-4 241903 13342
10
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
11
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
14
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
20
Doxil Approved June 1999 Phase 3,Phase 1 31703
21
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antibodies Phase 3,Phase 2,Phase 1
24 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Immunoglobulins Phase 3,Phase 2,Phase 1
28 insulin Phase 3
29 Insulin, Globin Zinc Phase 3
30 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3,Phase 2,Phase 1
34 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Alkylating Agents Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2
46 Dermatologic Agents Phase 3
47 Folic Acid Antagonists Phase 3,Phase 2
48 Isophosphamide mustard Phase 3 0
49 Mitomycins Phase 3
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 104)

# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
13 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
14 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
15 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
17 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
18 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
19 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
20 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
21 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
22 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
23 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
24 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
25 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
26 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
27 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
28 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
29 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
30 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
31 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
32 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
34 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
36 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
37 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
38 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
39 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
40 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
41 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
42 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
43 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
44 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
45 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
46 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
47 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
48 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
49 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 cisplatin
50 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

38
Cervix, Lung, Pancreas, Lymph Node, Breast, Colon, Liver

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 527)
# Title Authors Year
1
A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration. ( 29069702 )
2018
2
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 28465645 )
2017
3
Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. ( 28123305 )
2017
4
Clinicopathological features and prognosis of gastric adenosquamous carcinoma. ( 28676632 )
2017
5
Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma. ( 29085501 )
2017
6
Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a<i>CDKN2A</i>germline mutation carrier. ( 28979722 )
2017
7
Importance of tumor extent in adenosquamous carcinoma of the head and neck: a retrospective cohort study. ( 28412233 )
2017
8
Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. ( 29258074 )
2017
9
Spontaneous pulmonary adenosquamous carcinoma in a free-living black capuchin monkey (Sapajus nigritus). ( 29283438 )
2017
10
Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. ( 28784574 )
2017
11
Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy. ( 28493097 )
2017
12
Genomic signatures of pancreatic adenosquamous carcinoma (PASC). ( 28722109 )
2017
13
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. ( 29203990 )
2017
14
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
15
The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma. ( 28397462 )
2017
16
Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. ( 28816351 )
2017
17
CD117 expression in adenosquamous carcinoma. ( 28766737 )
2017
18
Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. ( 28098663 )
2017
19
Adenosquamous Carcinoma of the Tongue. ( 29243024 )
2017
20
Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report. ( 28357109 )
2017
21
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. ( 28848104 )
2017
22
Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report. ( 29145336 )
2017
23
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
24
Primary Colon Adenosquamous Carcinoma in a Patient With Lynch Syndrome: A New Histologic Subtype Associated With Microsatellite Instability? ( 27422471 )
2016
25
Characterization of primary pulmonary adenosquamous carcinoma-associated pleural effusion. ( 26797868 )
2016
26
Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. ( 27039322 )
2016
27
A case of adenosquamous carcinoma of the lower bile duct diagnosed preoperatively via transpapillary biopsy. ( 27498940 )
2016
28
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. ( 27514842 )
2016
29
Primary cutaneous adenosquamous carcinoma of the penis: the first characterization of HPV status in this rare and diagnostically challenging entity with review of glandular carcinomas of the penis. ( 27696488 )
2016
30
Oral adenosquamous carcinoma: Report of a rare entity with a special insight on its histochemistry. ( 27721632 )
2016
31
Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report. ( 26870254 )
2016
32
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. ( 28028992 )
2016
33
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. ( 27918216 )
2016
34
Adenosquamous Carcinoma of the Duodenum: a Rare Entity. ( 27872539 )
2016
35
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. ( 27646608 )
2016
36
Analysis of SEER Adenosquamous Carcinoma Data to Identify Cause Specific Survival Predictors and Socioeconomic Disparities. ( 26838235 )
2016
37
Primary adenosquamous carcinoma of the liver: a case report. ( 28081592 )
2016
38
MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 27748889 )
2016
39
The Squamous Cells of Adenosquamous Carcinoma (ASCC) of the Prostate Might Represent a Terminally Differentiated Quiescent Component: Immunohistochemical Evidence From a Case of ASCC With Pleomorphic Giant Tumor Cells. ( 27753662 )
2016
40
(18)F-FDG PET/CT in a case of primary hepatic adenosquamous carcinoma. ( 27033745 )
2016
41
Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience. ( 27002010 )
2016
42
Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. ( 27295533 )
2016
43
Adenosquamous carcinoma of the tongue: clinicopathologic study and review of the literature. ( 27456683 )
2016
44
Pulmonary micropapillary-type adenosquamous carcinoma sharing epidermal growth factor receptor mutation in adenocarcinoma and squamous cell carcinoma. ( 28127432 )
2016
45
A Case of Pancreatic Adenosquamous Carcinoma Obstructing the Common Bile and Pancreatic Ducts, Duodenum, and Gastric Outlet. ( 26863381 )
2016
46
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
47
Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. ( 28034323 )
2016
48
Oral Adenosquamous Carcinoma Mimicking a Pyogenic Granuloma: a Challenging Diagnosis. ( 27982195 )
2016
49
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
50
Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? ( 27096255 )
2016

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 EGFR KRAS KRT18 KRT5 KRT7 KRT8
2
Show member pathways
12.55 EGFR KRAS PDGFRA TP53
3
Show member pathways
12.47 EGFR KRAS PDGFRA TP53
4
Show member pathways
12.39 EGFR KRAS PDGFRA TP53
5
Show member pathways
12.3 EGFR KRAS PDGFRA TP53
6
Show member pathways
12.27 KRT18 KRT5 KRT7 KRT8
7
Show member pathways
12.22 EGFR KRAS PDGFRA TP53
8
Show member pathways
12.22 EGFR KRAS MUC1 TP53
9 12.21 KRT18 KRT5 KRT7 KRT8 MUC1
10 12.13 EGFR KRAS PDGFRA TP53 TP63
11
Show member pathways
12.03 EGFR KRAS PDGFRA TP53
12 11.99 EGFR KRAS TP53
13
Show member pathways
11.98 EGFR KRAS TP53
14
Show member pathways
11.96 EGFR KRAS PDGFRA
15 11.88 EGFR TP53 TP63
16
Show member pathways
11.87 EGFR KRAS TP53
17 11.87 EGFR KRAS TP53
18 11.64 EGFR KRAS PDGFRA
19 11.5 EGFR KRAS TP53
20 11.5 EGFR KRAS PDGFRA TP53
21 11.29 EGFR PDGFRA TP53
22
Show member pathways
11.29 KRT18 KRT5 KRT7 KRT8
23 11.17 EGFR KRAS PDGFRA
24
Show member pathways
10.93 TP53 TP63
25 10.74 EGFR KRAS PDGFRA TP53

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.73 CCT2 EGFR KRAS KRT18 KRT5 KRT7
2 intermediate filament GO:0005882 9.46 KRT18 KRT5 KRT7 KRT8
3 keratin filament GO:0045095 8.92 KRT18 KRT5 KRT7 KRT8

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 KRT18 KRT7 KRT8 PDGFRA TP53
2 keratinization GO:0031424 9.67 KRT18 KRT5 KRT7 KRT8
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.65 KRAS MUC1 MUC4
4 wound healing GO:0042060 9.63 EGFR PDGFRA TP53
5 response to X-ray GO:0010165 9.49 TP53 TP63
6 cornification GO:0070268 9.46 KRT18 KRT5 KRT7 KRT8
7 hepatocyte apoptotic process GO:0097284 9.43 KRT18 KRT8
8 cellular response to reactive oxygen species GO:0034614 9.43 EGFR PDGFRA TP53
9 mitotic G1 DNA damage checkpoint GO:0031571 9.4 TP53 TP63
10 epidermis development GO:0008544 9.26 EGFR KRT5 PTHLH TP63
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 MUC1 TP53 TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 p53 binding GO:0002039 9.33 MUC1 TP53 TP63
2 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 TP63
3 scaffold protein binding GO:0097110 8.8 KRT18 KRT5 KRT8

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....